Potential of flavonoids as anti-Alzheimer's agents: bench to bedside

Environ Sci Pollut Res Int. 2022 Apr;29(18):26063-26077. doi: 10.1007/s11356-021-18165-z. Epub 2022 Jan 24.

Abstract

Developing therapies for neurodegenerative diseases are challenging because of the presence of blood-brain barrier and Alzheimer being one of the commonest and uprising neurodegenerative disorders possess the need for developing novel therapies. Alzheimer's is attributed to be the sixth leading cause of death in the USA and the number of cases is estimated to be increased from 58 million in 2021 to 88 million by 2050. Natural drugs have benefits of being cost-effective, widely available, fewer side effects, and immuno-booster can be useful in managing Alzheimer. Flavonoids can slow the neuronal degeneration as they have shown activity in central nervous system and are able to cross the blood-brain barrier. These can be easily extracted from fruits, vegetable, and plants. In Alzheimer disease, flavonoids scavenges the reactive oxygen species and reduces the production of amyloid beta protein. Agents from sub-classes of flavonoids such as flavanones, flavanols, flavones, flavonols, anthocyanins, and isoflavones having pharmacological action in treating Alzheimer disease are discussed in this review.

Keywords: Alzheimer’s disease; Anthocyanins; Anti-inflammatory; Feuroprotective; Flavanols; Flavanones; Flavonoids; Isoflavones.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Amyloid beta-Peptides
  • Anthocyanins
  • Flavanones*
  • Flavonoids / pharmacology
  • Humans

Substances

  • Amyloid beta-Peptides
  • Anthocyanins
  • Flavanones
  • Flavonoids